Elucidation of the mechanisms underlying cardioprotection by long-acting and ultrrashort-acting beta blockers in cardiac surgery

Elucidation of the mechanisms underlying cardioprotection by long-acting and ultrrashort-acting beta blockers in cardiac surgery - The role of beta-blocker on cardiac surgery

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004699

Enrollment

100

Registered

2010-12-15

Start date

2010-12-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients undergoing cardiac bypass surgery

Interventions

beta-blocker non beta-blocker

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients undergoing cardiac bypass surgery Patients undergoing valve plasty and valve replacement

Exclusion criteria

Exclusion criteria: Sever Liver Disease, Muscle Disease

Design outcomes

Primary

Measure	Time frame
Plasma fatty acid binding protein, and brain natriuretic peptide concentration was measured during the perioperative period of cardiac bypass surgery.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026